110 related articles for article (PubMed ID: 10697522)
21. Induction of p53-mediated apoptosis and recovery of chemosensitivity through p53 transduction in human glioblastoma cells by cisplatin.
Park CM; Park MJ; Kwak HJ; Moon SI; Yoo DH; Lee HC; Park IC; Rhee CH; Hong SI
Int J Oncol; 2006 Jan; 28(1):119-25. PubMed ID: 16327987
[TBL] [Abstract][Full Text] [Related]
22. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human.
Bergamaschi D; Samuels Y; O'Neil NJ; Trigiante G; Crook T; Hsieh JK; O'Connor DJ; Zhong S; Campargue I; Tomlinson ML; Kuwabara PE; Lu X
Nat Genet; 2003 Feb; 33(2):162-7. PubMed ID: 12524540
[TBL] [Abstract][Full Text] [Related]
23. Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point.
Wang LH; Okaichi K; Ihara M; Okumura Y
Anticancer Res; 1998; 18(1A):321-5. PubMed ID: 9568097
[TBL] [Abstract][Full Text] [Related]
24. p53 status of newly established acute myeloid leukaemia cell lines.
Zheng A; Castren K; Säily M; Savolainen ER; Koistinen P; Vähäkangas K
Br J Cancer; 1999 Feb; 79(3-4):407-15. PubMed ID: 10027306
[TBL] [Abstract][Full Text] [Related]
25. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells.
Hao J; Song X; Song B; Liu Y; Wei L; Wang X; Yu J
Cancer Gene Ther; 2008 Jul; 15(7):449-55. PubMed ID: 18421307
[TBL] [Abstract][Full Text] [Related]
26. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
[TBL] [Abstract][Full Text] [Related]
27. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
28. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
29. P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line SAOS-2.
Zuffa E; Mancini M; Brusa G; Pagnotta E; Hattinger CM; Serra M; Remondini D; Castellani G; Corrado P; Barbieri E; Santucci MA
Int J Radiat Biol; 2008 Jul; 84(7):591-601. PubMed ID: 18661375
[TBL] [Abstract][Full Text] [Related]
30. [Effects of wild-type p53 gene on the chemotherapy sensitivity of ovarian cancer SKOV-3 cells to cisplatin].
Jin Z; Guan T; Li S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2002 Jun; 19(3):218-20. PubMed ID: 12048682
[TBL] [Abstract][Full Text] [Related]
31. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
[TBL] [Abstract][Full Text] [Related]
32. Sensitizing effect of galectin-7 in urothelial cancer to cisplatin through the accumulation of intracellular reactive oxygen species.
Matsui Y; Ueda S; Watanabe J; Kuwabara I; Ogawa O; Nishiyama H
Cancer Res; 2007 Feb; 67(3):1212-20. PubMed ID: 17283157
[TBL] [Abstract][Full Text] [Related]
33. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
34. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
[TBL] [Abstract][Full Text] [Related]
35. Cisplatin resistance conferred by the RAD51D (E233G) genetic variant is dependent upon p53 status in human breast carcinoma cell lines.
Nadkarni A; Rajesh P; Ruch RJ; Pittman DL
Mol Carcinog; 2009 Jul; 48(7):586-91. PubMed ID: 19347880
[TBL] [Abstract][Full Text] [Related]
36. Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.
Mueller T; Voigt W; Simon H; Fruehauf A; Bulankin A; Grothey A; Schmoll HJ
Cancer Res; 2003 Jan; 63(2):513-21. PubMed ID: 12543810
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
38. The p53-stabilizing compound, CP-31398, does not enhance chemosensitivity in human melanoma cells.
Luu Y; Li G
Anticancer Res; 2003; 23(1A):99-105. PubMed ID: 12680200
[TBL] [Abstract][Full Text] [Related]
39. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
40. P53 gene abnormalities in osteosarcoma.
Guo W; Wang X; Feng C
Chin Med J (Engl); 1996 Oct; 109(10):752-5. PubMed ID: 9275350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
